Scinai Immunotherapeutics Ltd. (SCNI)

0.4499 +0.0181 (+4.19%) 收市：04:00PM EDT

Scinai Immunotherapeutics Ltd.

Jerusalem BioPark Building
2nd floor Hadassah Ein Kerem Campus
Jerusalem
Israel
972 8 930 2529
https://www.scinai.com

版塊: Healthcare
行業: Biotechnology
全職員工: 33

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Amir Reichman M.B.A., M.Sc.	CEO & Director	562.5k	無	1976
Mr. Elad Mark B.Sc., Eng., M.B.A.	Chief Operating Officer	277.02k	無	1983
Dr. Tamar Ben-Yedidia Ph.D.	Chief Science Officer	314.92k	無	1964
Mr. Uri Ben-Or CPA, CPA, M.B.A., MBA	Chief Financial Officer	582k	無	1970
Dr. Dalit Weinstein Fischer Ph.D.	Chief Technology Officer	無	無	無
Mr. Joshua E. Phillipson B.Sc., M.B.A.	Director of Communications & Investor Relations	無	無	無
Liat Halpert	Head of Business Development & Sales	無	無	無
Merav Kamensky	Head of Quality Control	無	無	無

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

公司管治

截至 無 止，Scinai Immunotherapeutics Ltd. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。